A single dose of Ixchiq induced a high and sustained immune response in 99.1% of adolescents, according to Valneva.

GSK plc (NYSE:GSK) released topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, ...

This post was written and published as a collaboration between the in-house editorial team at Benzinga and Tonix ...

This summary covers significant updates in the health sector, including US Senator Bernie Sanders' push for cheaper generic ...

Catching the virus that causes COVID-19 or getting a COVID-19 vaccination gives you protection, also called immunity, from the virus. But over time, that protection seems to ...

GSK plc (LSE/NYSE: GSK) today announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, reactogenicity and safety of AREXVY (Respiratory ...

This guide will walk you through how to get the updated COVID-19 vaccine for free in NYC, even if you are undocumented or ...

The FDA should have more big news for Vertex only a few weeks later. It expects to announce an approval decision on ...

Readers are undoubtedly confused by the reference to 1000 percent tariffs on prescription drugs. We don’t call our protection ...

Valneva SE (VALN) said that it has submitted label extension applications to the European Medicines Agency (EMA) and Health Canada to ...

Jim Cramer’s 10 Best Stock Picks for Investors Right Now. In this article, we are going to take a look at where Moderna, Inc.

Valneva expects to submit data to the U.S. Food and Drug Administration (FDA) this year to also support potential label extensions in the U.S. IXCHIQ ® is the world’s first and only licensed ...